SCHEMBL19949869

SCHEMBL19949869

CNCc1cc(C)c(-c2nc3c(-c4ccc(N5CCN(C)CC5)nc4)n[nH]c3cc2C#N)c(F)c1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 9/20 0.45
FLT3 P36888 5/20 0.45
NTRK1 P04629 5/20 0.45
KIT P10721 4/20 0.45
ACVR1 Q04771 3/20 0.41
FGFR1 P11362 1/20 0.41
FGFR2 P21802 1/20 0.41
FGFR3 P22607 1/20 0.41
BMPR1A P36894 1/20 0.41
TGFBR1 P36897 1/20 0.41
ACVRL1 P37023 1/20 0.41
HAMP P81172 1/20 0.41
PLK4 O00444 1/20 0.37
PARP1 P09874 1/20 0.36
TDO2 P48775 1/20 0.36
RET P07949 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19949764 0.90 MAP4K1 (0.46) MAP4K1FLT3NTRK1KITACVR1
SCHEMBL19960797 0.89 MAP4K1 (0.46) MAP4K1FLT3NTRK1KITACVR1
SCHEMBL19949883 0.86 MAP4K1 (0.46) MAP4K1FLT3ACVR1FGFR1FGFR2
SCHEMBL19949930 0.82 MAP4K1 (0.44) MAP4K1FLT3NTRK1KITFGFR3
SCHEMBL19949834 0.82 MAP4K1 (0.41) MAP4K1FLT3NTRK1KITFGFR1
SCHEMBL19949830 0.82 MAP4K1 (0.63) MAP4K1FLT3NTRK1KITFGFR1
SCHEMBL19949839 0.82 MAP4K1 (0.41) MAP4K1FLT3NTRK1KITPARP1
SCHEMBL19949911 0.82 MAP4K1 (0.41) MAP4K1FLT3NTRK1KIT
SCHEMBL19949874 0.80 NTRK1 (0.44) MAP4K1FLT3NTRK1KIT
SCHEMBL19964796 0.80 MAP4K1 (0.42) MAP4K1FLT3NTRK1KITFGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12516059-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2026-01-06 US claimed
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-11-21 US claimed
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-10-17 US claimed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US claimed
US-12516059-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2026-01-06 US disclosed
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-11-21 US disclosed
US-11891388-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2024-02-06 US disclosed
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2022-07-21 US disclosed
US-11242343-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2022-02-08 US disclosed
US-11242343-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2022-02-08 US disclosed
US-20200283434-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-09-10 US disclosed
US-20200283434-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-09-10 US disclosed
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-10-17 US disclosed
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-10-17 US disclosed
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed
WO-2018049214-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383889-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885FLT3 2404/4885NTRK1 2377/4885
US-11242343-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885FLT3 2404/4885NTRK1 2377/4885
US-20190315743-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885FLT3 2404/4885NTRK1 2377/4885
US-20180072718-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885FLT3 2404/4885NTRK1 2377/4885
US-20200283434-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885FLT3 2404/4885NTRK1 2377/4885
US-20220227752-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 MAP4K1 41/4885FLT3 2404/4885NTRK1 2377/4885
US-11891388-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 MAP4K1 41/4885FLT3 2404/4885NTRK1 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.